8.62
0.11 (1.29%)
| 前收盘价格 | 8.51 |
| 收盘价格 | 8.58 |
| 成交量 | 1,315,618 |
| 平均成交量 (3个月) | 1,190,633 |
| 市值 | 912,728,704 |
| 价格/销量 (P/S) | 6.10 |
| 股市价格/股市净资产 (P/B) | 1.84 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 - 8 Aug 2025 |
| 营业毛利率 | -277.30% |
| 营业利益率 (TTM) | -435.71% |
| 稀释每股收益 (EPS TTM) | -4.23 |
| 季度收入增长率 (YOY) | -80.70% |
| 总债务/股东权益 (D/E MRQ) | 15.25% |
| 流动比率 (MRQ) | 5.37 |
| 营业现金流 (OCF TTM) | -300.00 M |
| 杠杆自由现金流 (LFCF TTM) | -174.00 M |
| 资产报酬率 (ROA TTM) | -22.25% |
| 股东权益报酬率 (ROE TTM) | -63.17% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Arcus Biosciences, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.60 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 34.86% |
| 机构持股比例 | 65.05% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2024 | 30,061,124 |
| Invus Financial Advisors, Llc | 30 Jun 2024 | 1,612,077 |
| Siren, L.L.C. | 31 Dec 2024 | 1,612,077 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,602,200 |
| Boxer Capital Management, Llc | 31 Dec 2024 | 1,602,200 |
| Parkman Healthcare Partners Llc | 31 Dec 2024 | 1,273,789 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 26.00 (Wells Fargo, 201.62%) | 购买 |
| 中 | 18.00 (108.82%) | |
| 低 | 13.00 (Goldman Sachs, 50.81%) | 保留 |
| 平均值 | 18.75 (117.52%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 8.23 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 09 May 2025 | 22.00 (155.22%) | 购买 | 8.28 |
| Goldman Sachs | 08 May 2025 | 13.00 (50.81%) | 保留 | 8.53 |
| Wells Fargo | 07 May 2025 | 26.00 (201.62%) | 购买 | 8.01 |
| Barclays | 23 Apr 2025 | 14.00 (62.41%) | 购买 | 8.11 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合